Measuring Critical Health Outcomes Beyond Weight Loss In GLP-1 And Related Obesity Treatments

The advent of GLP-1 receptor agonists has revolutionized obesity treatment, with weight loss being a key measure of efficacy. However, concerns have emerged regarding the potential loss of lean muscle mass during treatment, which could have adverse short- and long-term health effects. In this context, the role of physical activity and cardiovascular fitness in obesity management is critical. Dr. Glenn Gaesser, a leading expert on the relationship between weight loss, physical activity, and health outcomes, emphasizes the importance of a fitness-centered approach to obesity treatment. Research indicates that increasing physical fitness, rather than focusing solely on weight loss, can significantly reduce mortality risk, even in individuals with higher BMI.

Objective, continuous data capture via digital health technologies (DHTs), including wearables, provides a more accurate picture of physical activity and its impact on health outcomes. These technologies, such as accelerometers and heart rate monitors, enable real-time tracking of physical activity, sleep, and other behavioral factors, offering valuable insights beyond weight change alone. Dr. Gaesser advocates for the inclusion of fitness and activity measures, such as cardiorespiratory fitness, daily physical activity, and sedentary behavior, in obesity treatment research.

Moreover, the integration of wearable DHTs in clinical trials offers an opportunity to enhance the measurement of physical activity and energy expenditure, which may help elucidate variations in treatment responses and optimize drug development. Collaborative efforts, like the DECODE: Obesity working group, are advancing the development of these digital measures to improve clinical trial outcomes and enhance the effectiveness of future obesity therapies.

Learn more by reading the full article below.